Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review

doi:10.4239/wjd.124799

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

This Article

(12)

(9)

(0)

(61)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Diabetes. Oct 15, 2026; 17(10): 124799
Published online Oct 15, 2026. doi: 10.4239/wjd.124799

Full Size Figure Download Figure

Figure 3 Evidence hierarchy and clinical interpretation framework for glucagon-like peptide-1 receptor agonist exposure around pregnancy. FAERS: United States Food and Drug Administration Adverse Event Reporting System; GLP-1RA: Glucagon-like peptide-1 receptor agonist; HDP: Hypertensive disorders of pregnancy; LGA: Large for gestational age; SRMA: Systematic review and meta-analysis.

Citation: Singh R, Singh A, Singh AK. Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review. World J Diabetes 2026; 17(10): 124799
URL: https://www.wjgnet.com/1948-9358/full/v17/i10/124799.htm
DOI: https://dx.doi.org/10.4239/wjd.124799

Singh R, Singh A, Singh AK. Human pregnancy outcomes after early glucagon-like peptide-1 receptor agonist exposure: A scoping review. World J Diabetes 2026; 17(10): 124799 [DOI: 10.4239/wjd.124799]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.